Tocilizumab prophylaxis in double cord blood transplantation.
作者信息
Drobyski William R
机构信息
Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood Adv. 2025 May 27;9(10):2585-2586. doi: 10.1182/bloodadvances.2024015785.
Abstract
摘要
相似文献
1
Tocilizumab prophylaxis in double cord blood transplantation.托珠单抗在双份脐血移植中的预防作用
Blood Adv. 2025 May 27;9(10):2585-2586. doi: 10.1182/bloodadvances.2024015785.
2
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.环孢素A、霉酚酸酯和托珠单抗预防脐带血移植中移植物抗宿主病的2期试验。
Blood Adv. 2025 May 27;9(10):2570-2584. doi: 10.1182/bloodadvances.2024014177.
3
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.托珠单抗治疗异基因造血细胞移植后使用环磷酰胺的移植物抗宿主病预防方案后发生细胞因子释放综合征
Transplant Cell Ther. 2023 Aug;29(8):515.e1-515.e7. doi: 10.1016/j.jtct.2023.05.008. Epub 2023 May 12.
4
Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.托珠单抗单药治疗或联合甲氨蝶呤治疗类风湿关节炎：一项随机临床试验。
JAMA Netw Open. 2025 May 1;8(5):e2511095. doi: 10.1001/jamanetworkopen.2025.11095.
5
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.异体造血干细胞移植后加用托珠单抗抑制白细胞介素-6 预防移植物抗宿主病：一项 1/2 期试验。
Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.
6
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.静脉注射候选生物类似药CT-P47与对照药托珠单抗的药代动力学及安全性：一项随机、双盲、1期研究
J Clin Pharmacol. 2025 Feb;65(2):233-241. doi: 10.1002/jcph.6139. Epub 2024 Oct 16.
7
Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells.托珠单抗通过促进血管内皮细胞紧密连接的恢复促进脊髓损伤的修复。
Fluids Barriers CNS. 2023 Jan 9;20(1):1. doi: 10.1186/s12987-022-00399-9.
8
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.使用体外扩增的脐带血移植的临床结局：对照研究的系统评价和荟萃分析。
Transplant Cell Ther. 2023 Feb;29(2):129.e1-129.e9. doi: 10.1016/j.jtct.2022.11.007. Epub 2022 Nov 15.
9
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.与接受基于移植后环磷酰胺的移植物抗宿主病预防的匹配无关供体移植相比，在处于首次完全缓解的急性髓系白血病患者中，接受双份脐带血移植的患者存活率更高：这是来自欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
Am J Hematol. 2024 Dec;99(12):2296-2305. doi: 10.1002/ajh.27466. Epub 2024 Aug 31.
10
Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.来特莫韦用于儿童患者异基因造血干细胞移植后巨细胞病毒预防的疗效和安全性
Drug Des Devel Ther. 2025 Jun 12;19:5059-5069. doi: 10.2147/DDDT.S513383. eCollection 2025.
本文引用的文献
1
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.环孢素A、霉酚酸酯和托珠单抗预防脐带血移植中移植物抗宿主病的2期试验。
Blood Adv. 2025 May 27;9(10):2570-2584. doi: 10.1182/bloodadvances.2024014177.
2
Mitigation of gastrointestinal graft--host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination.托珠单抗预防减轻胃肠道移植物抗宿主病的同时，伴随着微生物多样性的保留和肠球菌优势地位的减弱。
Haematologica. 2023 Jan 1;108(1):250-256. doi: 10.3324/haematol.2022.281309.
3
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.一项关于托珠单抗与安慰剂联合环孢素/甲氨蝶呤用于 GVHD 预防的 3 期双盲研究。
Blood. 2021 Apr 8;137(14):1970-1979. doi: 10.1182/blood.2020009050.
4
IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling.IL-6 失调起源于树突状细胞，并通过经典信号转导介导移植物抗宿主病。
Blood. 2019 Dec 5;134(23):2092-2106. doi: 10.1182/blood.2019000396.
5
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft--host disease: low incidence of lower gastrointestinal tract disease.托珠单抗、他克莫司和甲氨蝶呤预防急性移植物抗宿主病：下消化道疾病发生率低。
Haematologica. 2018 Apr;103(4):717-727. doi: 10.3324/haematol.2017.183434. Epub 2018 Jan 19.
6
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.异体造血干细胞移植后加用托珠单抗抑制白细胞介素-6 预防移植物抗宿主病：一项 1/2 期试验。
Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.
7
Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease.无关脐带血移植后预处理综合征：移植和急性移植物抗宿主病的预测因子。
Biol Blood Marrow Transplant. 2013 Apr;19(4):640-6. doi: 10.1016/j.bbmt.2013.01.014. Epub 2013 Feb 1.
8
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.白细胞介素-6 调节实验性同种异体骨髓移植后的移植物抗宿主反应。
Clin Cancer Res. 2011 Jan 1;17(1):77-88. doi: 10.1158/1078-0432.CCR-10-1198. Epub 2010 Nov 3.
9
Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.双份脐血移植后的植入前综合征：一种与急性移植物抗宿主病无关的独特综合征。
Biol Blood Marrow Transplant. 2010 Mar;16(3):435-40. doi: 10.1016/j.bbmt.2009.10.022. Epub 2009 Oct 24.
10
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.白细胞介素-6信号通路的阻断增强调节性T细胞重建并减轻移植物抗宿主病的严重程度。
Blood. 2009 Jul 23;114(4):891-900. doi: 10.1182/blood-2009-01-197178. Epub 2009 Jun 2.
Zotero 插件